The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.

Meanwhile, Pfizer reckons it's found the right dose for its KAT6.

The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.

The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Party season approaches; but first, conferences.

Syndax scored the first menin approval, but Kura is first with a licensing deal.